



**Sodium Glucose CoTransporter 2 (SGLT2) Inhibitors**  
**Steglatro (ertugliflozin)**  
**Segluromet (ertugliflozin/metformin)**  
**Glyxambi (empagliflozin/linagliptin)**  
**Duetact (glimepiride/pioglitazone)**  
**Qtern (dapagliflozin/saxagliptin)**  
**Repaglinide/metformin**  
**Steglujan (ertugliflozin/sitagliptin)**  
**Trijardy XR (empagliflozin/linagliptin/metformin extended release)**  
**Effective 11/01/2022**

<b>Plan</b>	<input type="checkbox"/> MassHealth <input checked="" type="checkbox"/> MassHealth (PUF) <input type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

**Overview**

Sodium-glucose cotransporter 2 (SGLT2) reduces reabsorption of filtered glucose from the tubular lumen and lowers the renal threshold for glucose (RT<sub>G</sub>). SGLT2 is the main site of filtered glucose reabsorption; reduction of filtered glucose reabsorption and lowering of RT<sub>G</sub> result in increased urinary excretion of glucose, thereby reducing plasma glucose concentrations.

No PA	PA required
Farxiga® (dapagliflozin)	Steglatro® (ertugliflozin)
Invokana® (canagliflozin)	Segluromet® (ertugliflozin/metformin)
Invokamet® (canagliflozin/metformin)	Glyxambi® (empagliflozin/linagliptin)
Jardiance® (empagliflozin)	Duetact® (glimepiride/pioglitazone) *§
Synjardy® (empagliflozin/metformin)	Qtern® (dapagliflozin/saxagliptin)
Synjardy XR® (empagliflozin/metformin extended-release)	repaglinide/metformin



Xigduo XR <sup>®</sup> (dapagliflozin/metformin extended-release)	Steglujan <sup>®</sup> (ertugliflozin/sitagliptin)
	Trijardy XR <sup>®</sup> (empagliflozin/linagliptin/ metformin extended-release)

# This is a brand-name drug with FDA "A"-rated generic equivalents. PA is required for the brand, unless a particular form of that drug (for example, tablet, capsule, or liquid) does not have an FDA "A"-rated generic equivalent.

\*A-rated generic available. Both brand and A-rated generic require PA.

†Authorized generic available. Both brand and authorized generic require PA.

<sup>PD</sup> Preferred Drug. In general, a trial of the preferred drug or clinical rationale for prescribing a non-preferred drug within a therapeutic class. Please note, for Trulicity<sup>®</sup> (dulaglutide) and GLP-1 receptor agonists, a trial with a preferred agent is not required prior to approval of a non-preferred agent.

§ Brand Preferred over generic equivalents. In general, a trial of the preferred drug or clinical rationale for prescribing the non-preferred drug generic equivalent.

### Coverage Guidelines

Authorizations requests will be reviewed on a case by case basis for members new to the plan who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

#### OR

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

**Duetact<sup>®</sup>** (glimepiride/pioglitazone)\*§

**Glyxambi<sup>®</sup>** (empagliflozin/linagliptin)

**Segluromet<sup>®</sup>** (ertugliflozin/ metformin)

**Steglujan<sup>®</sup>** (ertugliflozin/sitagliptin)

**Repaglinide/metformin**

**Trijardy XR<sup>®</sup>** (empagliflozin/linagliptin/ metformin extended-release)

1. Member has a diagnosis of Type 2 Diabetes Mellitus
2. **ONE** of the following:
  - a. Paid claims or physician attestation of inadequate response (defined as at least 90 days of therapy within a 120-day time period) to metformin used in combination with at least one of the non-metformin agents in the requested combination
  - b. **BOTH** of the following:
    - i. Adverse reaction or contraindication to metformin
    - ii. Paid claims or physician attestation of inadequate response (defined as at least 90 days of therapy within a 120-day time period) to at least one of the non-metformin agents in the requested combination
  - c. **BOTH** of the following:
    - i. Paid claims or physician attestation of inadequate response (defined as at least 90 days of therapy within a 120-day time period), adverse reaction or contraindication to metformin
    - ii. Adverse reaction to at least one of the non-metformin agents in the requested combination
3. If the request is for Trijardy XR, clinical rationale for use of the combination product instead of the commercially available separate agents

\*A-rated generic available. Both brand and A-rated generic require PA.

§ Brand Preferred over generic equivalents. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing the non-preferred drug generic equivalent.



**Steglatro® (ertugliflozin)**

Prescriber provides documentation of the following:

1. Member has a diagnosis of Type 2 Diabetes Mellitus
2. **ONE** of the following
  - a. Paid claims or physician attestation of inadequate response (defined as at least 90 days of therapy within a 120-day time period) to metformin used in combination with **ONE** of the following:
    - i. Farxiga® (dapagliflozin)
    - ii. Invokana® (canagliflozin)
    - iii. Jardiance® (empagliflozin)
  - b. **BOTH** of the following:
    - i. Paid claims or physician attestation of adverse reaction or contraindication to metformin
    - ii. Prescriber documented inadequate response (defined as at least 90 days of therapy within a 120-day time period) to **ONE** of the following:
      1. Farxiga® (dapagliflozin)
      2. Invokana® (canagliflozin)
      3. Jardiance® (empagliflozin)
  - c. **BOTH** of the following:
    - i. Paid claims or physician attestation of inadequate response (defined as at least 90 days of therapy within a 120-day time period), adverse reaction or contraindication to metformin
    - ii. Adverse reaction to **ONE** of the following:
      1. Farxiga® (dapagliflozin)
      2. Invokana® (canagliflozin)
      3. Jardiance® (empagliflozin)
  - d. **BOTH** of the following:
    - i. Paid claims or physician attestation of inadequate response (defined as at least 90 days of therapy within a 120-day time period), adverse reaction or contraindication to metformin
    - ii. Contraindication to **ALL** of the following:
      1. Farxiga® (dapagliflozin)
      2. Invokana® (canagliflozin)
      3. Jardiance® (empagliflozin)
3. If requested quantity exceeds 1 tablet/day, clinical rationale for exceeding FDA-approved dosing schedule

**Continuation of Therapy**

Reauthorization requires physician attestation of continuation of therapy and positive response to therapy.

**Limitations**

1. Initial approval and reauthorizations will be granted for 12 months.
2. The following quantity limits apply:

Farxiga® (dapagliflozin)	30 tablets per 30 days
Invokana® (canagliflozin)	30 tablets per 30 days
Invokamet® (canagliflozin/metformin)	60 tablets per 30 days
Jardiance® (empagliflozin)	30 tablets per 30 days
Synjardy® (empagliflozin/metformin)	60 tablets per 30 days

Steglatro <sup>®</sup> (ertugliflozin)	30 tablets per 30 days
Segluromet <sup>®</sup> (ertugliflozin/metformin)	60 tablets per 30 days
Glyxambi <sup>®</sup> (empagliflozin/linagliptin)	30 tablets per 30 days
Duetact <sup>®</sup> (glimepiride/pioglitazone)	30 tablets per 30 days
Qtern <sup>®</sup> (dapagliflozin/saxagliptin)	30 tablets per 30 days
Steglujan <sup>®</sup> (ertugliflozin/sitagliptin)	30 tablets per 30 days
Trijardy XR <sup>®</sup> (empagliflozin/linagliptin/metformin extended-release)	30 tablets per 30 days

## References

1. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Handelsman Y et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020. *Endocrine Practice*. 2020 Jan;26(1):107- 139.
2. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. *Diabetes Care*. 2021 Jan;44(Suppl 1):S111-S124.
3. Glyxambi<sup>®</sup> [package insert]. Indianapolis (IN): Eli Lilly and Company; 2021 Jun.
4. Qtern<sup>®</sup> [package insert on the Internet]. Wilmington (DE): AstraZeneca Pharmaceuticals. 2020 Jan.
5. Segluromet<sup>®</sup> [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.; 2021 Mar.
6. Steglatro<sup>®</sup> [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.; 2021 Mar.
7. Steglujan<sup>®</sup> [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.; 2021 Feb.
8. American Diabetes Association. 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2021. *Diabetes Care*. 2021 Jan;44(Suppl 1):S200-S210.
9. American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2021. *Diabetes Care*. 2021 Jan;44(Suppl 1):S34-S39.
10. Barbieri RL, Ehrmann DA. Metformin for treatment of the polycystic ovary syndrome. In: Basow DS (Ed). *UpToDate* [database on the internet]. Waltham (MA): UpToDate; 2021 [cited 2021 Aug 24]. Available from: <http://www.utdol.com/utd/index.do>.

## Review History

10/05/2020 – Implemented to match Masshealth partial unified formulary requirements for implementation on 1/1/21

11/17/2021 – Reviewed and Updated for Nov P&T; Qtern<sup>®</sup> (dapagliflozin/saxagliptin), repaglinide/metformin, Steglujan<sup>®</sup> (ertugliflozin/sitagliptin), and Trijardy XR<sup>®</sup> (empagliflozin/linagliptin/metformin extended-release) added to UPPL criteria. , Duetact<sup>®</sup> is brand preferred as noted in the reference table. Effective 1/1/2022

11/16/2022 – Reviewed and updated for Nov P&T. Matched MH. Added criteria C for Steglatro: requiring an inadequate response, adverse reaction or contraindication to metformin AND adverse reaction to one of the agents (Farxiga, Invokana, Jardiance). Clarified Trijardy XR QL to 30 tablets per 30 days. Effective 11/01/2022

## Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.